TY - JOUR
AU - Armstrong, Katrina A.
AB - Opinion EDITORIAL Katrina A. Armstrong, MD Cancer mortality in the United States has declined by about trial cancer, and aromatase inhibitors have been associated with 1,2 1.5% per year since 1999. Patients with most of the com- increased risk of possible cardiovascular events as well as va- mon solid tumors have experienced decreased mortality risk somotor and musculoskeletal symptoms. Per trial data, the ab- solute incidence of a major adverse effect (from 4 [95% CI, 1-8] over this period, including those with breast cancer, in whom mortality fell by 1.8% per year cases per 1000 women over 5 years of treatment for endome- between 1998 and 2016. Al- trial cancer to 7 [95% CI, 0.3-17] cases per 1000 women over 5 Audio though there is much to cel- years of treatment for venous thromboembolic events) can ap- ebrate in these statistics, there is still a long way to go. Breast proach the absolute benefit in breast cancer risk reduction cancer remains the second leading cause of cancer death among (from 7 [95% CI, 4-12] to 16 [95% CI, 8-24] fewer cases of breast US women, with an estimated 42 000 deaths in 2018. At this cancer per 1000 women 
TI - Maximizing the Outcomes of Breast Cancer Prevention
JF - JAMA Internal Medicine
DO - 10.1001/jamainternmed.2019.4666
DA - 2019-12-21
UR - https://www.deepdyve.com/lp/american-medical-association/maximizing-the-outcomes-of-breast-cancer-prevention-m7JWn9X0IZ
SP - 1621
EP - 1623
VL - 179
IS - 12
DP - DeepDyve
ER -